Information updates

Changes to IVIg supply

From 4 April 2022 the National Blood Authority (NBA) has advised that some patients will transition to another intravenous immunoglobulin (IVIg) product, who have the following conditions:

  • Pemphigus vulgaris
  • Pyoderma Gangrenosum
  • Bullous pemphigoid
  • Scleromyxedema
  • Immune thrombocytopenic purpura (ITP) adults only
  • Multifocal motor neuropathy (MMN)
  • Myasthenia gravis (MG)

Clinicians treating patients with the conditions listed above are aware of the change.

The NBA consulted with clinical experts through the National Immunoglobulin Governance Advisory Committee (NIGAC) to minimise the impact on the smallest number of patients possible.

Changing to another product can be stressful for the patient, clinician and hospital. Patients or carers should discuss any concerns with their treating clinician. Additionally, the NPS MedicineWise ViP Ig pamphlet Switching Immunoglobulin Products – What Should I know? What Can I Do? may be useful. More information is also available at

This news item was issued on 5 April 2022 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand.  

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia